Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals (JNP) to Discuss First Quarter 2015 Results on May 6th Conference Call

BOSTON, April 23, 2015 /PRNewswire/ -- The management team at Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), will hold a conference call on May 6, 2015, to discuss financial results for the first quarter ended March 31, 2015.  The call details are as follows:


Wednesday, May 6, 2015


8:30 AM EDT

Dial-in numbers:

Toll free: (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or,

International: (412) 317-0790

Webcast (live & archive):, under 'Investor' or click here

The teleconference replay will be available approximately one hour after completion through Friday, May 15, 2015, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10064719.  The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health.  Juniper has a successful heritage in developing pharmaceutical products, including CRINONE® 8% (progesterone gel), which is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 countries worldwide.  The Company is uniquely positioned to leverage in-house pharmaceutical development, clinical trial manufacturing, and analytical capabilities to advance an internal development pipeline, while also providing valuable consultative services to its pharmaceutical industry customers.  Please visit for more information.

Juniper Pharmaceuticals™ and Juniper Pharma Services™ are trademarks of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S.


Katja Buhrer

MBS Value Partners

(212) 661-7004


To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.